GSK (LSE:GSK) has received acceptance from the European Medicines Agency to review its marketing authorisation application for bepirovirsen, an antisense oligonucleotide therapy being developed as a potential first-in-class treatment for adults with chronic hepatitis B. The regulatory submission is supported by encouraging Phase III results from the B-Well trial, where bepirovirsen used alongside standard nucleos(t)ide analogue therapy delivered significantly higher functional cure rates compared with standard treatment alone, while maintaining an acceptable safety profile.
Chronic hepatitis B affects roughly 3.2 million people across Europe, many of whom require lifelong antiviral treatment. A finite therapy capable of achieving a functional cure could transform current treatment approaches and reduce long-term complications such as liver cancer. If approved, bepirovirsen would further strengthen GSK’s position in the infectious disease market and could serve as a core component in future combination regimens aimed at expanding functional cure rates among broader patient populations.
The company’s outlook is supported by strong profitability and improving fundamentals, alongside positive pipeline progress and constructive guidance for 2026. Valuation appears reasonable with a modest dividend yield, although near-term technical indicators suggest potential overbought conditions and there remain ongoing considerations around balance sheet dynamics and earnings consistency.
More about GSK
GSK is a global biopharmaceutical company focused on discovering, developing and commercialising medicines and vaccines to prevent and treat disease. The company applies advanced science and technology across therapeutic areas including infectious diseases, aiming to deliver innovative therapies that can prevent illness or transform the management of chronic conditions for patients worldwide.
Leave a Reply